Autoimmune disorders (AID) are chronic conditions that involve the loss of immunological
tolerance to self-antigens, and result in systemic or tissue-specific damage. Current …

Extracorporeal photopheresis (ECP) is a cell-based immunotherapy that involves the
reinfusion of autologous leukocytes after exposure to psoralen and UVA. The treatment has …

Extracorporeal photopheresis (ECP) is an autologous cell therapy that is widely used for the
treatment of T cell-mediated diseases. ECP has been FDA-approved for the treatment of …

The clinical use of extracorporeal photopheresis (ECP) for accepted indications such as
graft-versus-host disease, transplant rejection, and cutaneous T-cell lymphoma continues to …

The immune system is tasked with the unique challenge of recognizing foreign pathogens
and damaged cells while at the same time preserving and protecting the integrity of “self” …

Extracorporeal photopheresis (ECP) is a well‐tolerated procedure that suppresses T‐
lymphocyte activity in a clonally‐specific way. It is an effective therapy that has established …

Extracorporeal phototherapy (ECP) is a therapeutic approach based on the biological effect
of psoralen 8-methoxypsoralen (8-MOP) and ultraviolet light A (UVA) on mononuclear cells …

Extracorporeal photopheresis (ECP) has had a major impact in the treatment of various
conditions in the past 25 years. Although it was initially developed for the treatment of …

Extracorporeal photochemotherapy (ECP) is considered as an immune modulating therapy
majorly targeting the T cells of the Immune system. ECP induces an anti-inflammatory …

Extracorporeal photopheresis (ECP) has been in clinical use for over three decades after
receiving FDA approval for the palliative treatment of the Sézary Syndrome variant of …